Long-term Effects of Phosphodiesterase-5 Inhibitors on Cardiovascular Outcomes and Death: A Systematic Review and Meta-analysis.
Stergios SoulaidopoulosDimitrios Terentes-PrintziosNikolaos IoakeimidisKonstantinos P TsioufisCharalambos VlachopoulosPublished in: European heart journal. Cardiovascular pharmacotherapy (2024)
The use of PDE5i primarily in men with or without known coronary artery disease was associated with a lower risk for cardiovascular events and overall mortality. This information underlines that PDE5i could provide clinical benefit beyond ED treatment and could instigate the conduction of further, large-scale randomized clinical trials.
Keyphrases
- cardiovascular events
- coronary artery disease
- cardiovascular disease
- emergency department
- percutaneous coronary intervention
- coronary artery bypass grafting
- clinical trial
- heart failure
- type diabetes
- aortic stenosis
- combination therapy
- acute coronary syndrome
- atrial fibrillation
- aortic valve
- replacement therapy
- smoking cessation